MRTX - Mirati Will Continue To Shine As It Keeps Delivering Promising Results
- Mirati achieves positive results in phase 2 open-label study using sitravatinib to treat patients with metastatic or advanced urothelial carcinoma who have the KRAS mutation.
- Sitravatinib is a multi-kinase drug that targets RTK pathway which includes TAM family, VEGFR2 and KIT; This drug helps checkpoint inhibitors overcome the resistance of the tumor microenvironment.
- MRTX849 is a KRAS G12C inhibitor being used alone or in combination with other drugs like some checkpoint inhibitors to treat several types of cancer that have the KRAS mutation.
- A presentation of the basket phase 1/2 KRYSTAL study using monotherapy MRTX849 for the treatment of patients with NSCLC, colorectal cancer and pancreatic cancer will be shown at the Triple (EORTC-NCI-AACR) meeting October 2020.
For further details see:
Mirati Will Continue To Shine As It Keeps Delivering Promising Results